AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: STRONG — reflects the venue and review process. — venue and review process.

Validated HPLC method for clofazimine and pyrazinamide analysis

A person in white protective gloves and lab coat adjusts or operates a yellow and blue HPLC instrument control panel or detector unit mounted on laboratory equipment.
Research area:ChromatographyAnalytical Methods in PharmaceuticalsAnalytical Chemistry and Chromatography

What the study found

The study developed an RP-DAD-HPLC method to quantify clofazimine and pyrazinamide in a fixed-dose combination topical drug delivery system.

Why the authors say this matters

The authors state that reversed-phase high-performance liquid chromatography with diode-array detection can improve selectivity, accuracy, and reliability when testing drugs with different chemical properties in a single dosage form.

What the researchers tested

The researchers developed a chromatographic method using a C18 column, gradient elution, 0.1% aqueous formic acid and acetonitrile as mobile phases, and detection at 254 nm for pyrazinamide and 284 nm for clofazimine. They validated the method according to ICH Q2 guidelines and evaluated robustness with a three-level Box-Behnken design and response surface methodology.

What worked and what didn't

The method showed linearity from 7.8 to 500.0 µg/mL with r² = 0.9999. System repeatability was %RSD ≤ 2.7%, and intermediate precision from 25 to 500 µg/mL was %RSD ≤ 0.85%. Specificity was assessed for interference from solvents, product matrix, and degradation products, but the abstract does not report detailed failures or comparative performance problems.

What to keep in mind

The abstract does not describe limitations beyond the validation conditions reported. No clinical or product performance outcomes are given, and the summary is limited to the analytical method and its validation.

Key points

  • An RP-DAD-HPLC method was developed for clofazimine and pyrazinamide.
  • The method was intended for a fixed-dose combination topical drug delivery system.
  • Validation followed ICH Q2 guidelines and included specificity, linearity, repeatability, and intermediate precision.
  • Linearity was reported from 7.8 to 500.0 µg/mL with r² = 0.9999.
  • Robustness was assessed with a Box-Behnken design and response surface methodology.

Disclosure

Research title:
Validated HPLC method for clofazimine and pyrazinamide analysis
Authors:
Marius Brits, Francelle Bouwer, Joe M. Viljoen
Institutions:
North-West University
Publication date:
2026-01-21
OpenAlex record:
View
AI provenance: This post was generated by OpenAI. The original authors did not write or review this post.